2025/08/31 更新

所属以外の情報はresearchmapへの登録情報を転載しています。

写真a

フジタ　シンタロウ
藤田 真太朗
Shintaro Fujita
所属
附属病院 整形外科 助教
職名
助教
外部リンク

論文

  • PNI is useful for predicting the prognosis of patients with soft tissue sarcoma: A retrospective study.

    Keiju Saito, Yusuke Kawabata, Ikuma Kato, Satoru Shinoda, Kenta Hayashida, Shintaro Fujita, Tomotaka Yoshida, Hyonmin Choe, Masanobu Takeyama, Yutaka Inaba

    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association   2024年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: It is known that preoperative Prognostic Nutritional Index (PNI) is useful in predicting prognosis in gastrointestinal diseases and that preoperative improvement of nutritional status improves prognosis. However, there have been few large-scale reports examining the prognostic value of PNI in soft tissue sarcomas. Therefore, the aim of this study is to investigate whether the PNI can be useful for predicting overall survival in soft tissue sarcoma. METHODS: Between January 2006 and March 2022 at our hospital, 111 patients with pathologically diagnosed soft tissue sarcoma were included, retrospectively. Several nutritional or inflammatory biomarkers such as PNI were calculated from the pretreatment blood sample results. The patients were classified into two groups (low and high groups) based on the median value of each parameter. Overall survival was analyzed by the Kaplan‒Meier method and log-rank test. Univariate and multivariate analyses using the Cox proportional hazards model were used to investigate prognostic factors for overall survival. RESULTS: The median overall survival was 24.3 months (mean 37.3 months), and the high PNI group had a significantly longer overall survival than the low PNI group (p < 0.0001). PNI was the most significant univariate factor for overall survival among other nutritional and inflammatory parameters (HR: 5.64, 95% CI: 2.26-14.12, p = 0.0002). The multivariate proportional hazards model was built using variables with prognostic potential as suggested by previous analysis with respect to patient characteristics and PNI. As potential confounding factors, we included PNI, stage, age, and tumor location. PNI was also an independent prognostic factor in multivariate analysis (HR: 7.02, CI: 2.52-19.40, p = 0.0002). CONCLUSION: PNI is a useful prognostic factor among various parameters for overall survival in patients with soft tissue sarcoma.

    DOI： 10.1016/j.jos.2024.08.005

    PubMed

    researchmap

  • Prognostic nutritional indexによる軟部肉腫の予後予測

    斎藤 桂樹, 川端 佑介, 加藤 生真, 林田 健太, 吉田 智隆, 藤田 真太朗, 崔 賢民, 竹山 昌伸, 稲葉 裕

    日本整形外科学会雑誌   97 ( 8 )   S1893 - S1893   2023年8月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本整形外科学会  

    researchmap

  • Prognostic nutritional indexの軟部肉腫の予後予測における有用性

    斎藤 桂樹, 川端 佑介, 加藤 生真, 林田 健太, 吉田 智隆, 藤田 真太朗, 崔 賢民, 竹山 昌伸, 稲葉 裕

    日本整形外科学会雑誌   97 ( 6 )   S1334 - S1334   2023年6月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本整形外科学会  

    researchmap

  • 治療開始前PET-CTのSUVmaxを用いた軟部肉腫患者における悪性度予測

    川端 佑介, 斎藤 桂樹, 加藤 生真, 林田 健太, 吉田 智隆, 藤田 真太朗, 竹山 昌伸, 稲葉 裕

    日本整形外科学会雑誌   97 ( 6 )   S1463 - S1463   2023年6月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本整形外科学会  

    researchmap

  • 軟部肉腫の予後予測におけるprognostic nutritional indexの有用性

    斎藤 桂樹, 川端 佑介, 加藤 生真, 林田 健太, 吉田 智隆, 藤田 真太朗, 竹山 昌伸, 稲葉 裕

    日本整形外科学会雑誌   97 ( 2 )   S325 - S325   2023年3月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本整形外科学会  

    researchmap

  • 軟部肉腫患者における治療開始前PET-CTのSUVmaxを用いた悪性度予測

    川端 佑介, 斎藤 桂樹, 加藤 生真, 林田 健太, 吉田 智隆, 藤田 真太朗, 竹山 昌伸, 稲葉 裕

    日本整形外科学会雑誌   97 ( 3 )   S836 - S836   2023年3月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本整形外科学会  

    researchmap

  • A rare case of intra-articular synovial sarcoma of the hip joint: a case report with intra-articular findings via hip arthroscopy. 国際誌

    Keiju Saito, Yusuke Kawabata, Naomi Kobayashi, Hiromichi Iwashita, Ikuma Kato, Masako Otani, Kenta Hayashida, Shintaro Fujita, Tomotaka Yoshida, Hyonmin Choe, Masanobu Takeyama, Yutaka Inaba

    Journal of surgical case reports   2023 ( 2 )   rjad066   2023年2月

    　詳細を見る

    記述言語：英語  

    Although synovial sarcoma is a relatively common soft tissue sarcoma, primary intra-articular cases are extremely rare. Herein, we report a case of primary intra-articular synovial sarcoma arising from the hip joint, that was initially treated with hip arthroscopy. A 42-year-old male presented with a history of pain in the left hip for 7 years. Radiography and magnetic resonance imaging revealed the primary intra-articular lesion and simple excision with an arthroscopy was performed. Histological findings revealed spindle cell proliferation with abundant psammoma bodies. SS18 gene rearrangement was confirmed by fluorescence in situ hybridization, and the tumor was diagnosed as synovial sarcoma. Adjuvant chemotherapy and radiotherapy were performed. Local control without metastasis was achieved 6 months after excision. This is the first case of intra-articular synovial sarcoma of the hip joint excised via hip arthroscopy. When an intra-articular lesion is identified, malignancies such as synovial sarcoma should be included in the differential diagnosis.

    DOI： 10.1093/jscr/rjad066

    PubMed

    researchmap

  • Tranilast reduces the frequency of invasive treatment for extra-abdominal desmoid fibromatosis. 査読

    Shintaro Fujita, Masanobu Takeyama, Shingo Kato, Yusuke Kawabata, Yutaka Nezu, Kenta Hayashida, Keiju Saito, Kato Ikuma, Kota Washimi, Hyonmin Choe, Toru Hiruma, Yutaka Inaba

    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi   2022年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BackgroundThe active surveillance (AS) has been suggested for the initial treatment of extra-abdominal desmoid fibromatosis (EADF), the percentage of patients who shifted to invasive secondary treatments was significant. Tranilast, an anti-keloid medication, is frequently used in Japan, but there is no detailed report on its efficacy.MethodsWe retrospectively analyzed the medical records of EADF patients treated with tranilast between January 2009 and March 2021. Since EADF has been reported to shrink spontaneously, the effects of all drugs should be compared to AS. Therefore, we compared its clinical course with that under AS (determined by a systematic review) to assess the effect of tranilast. A systematic literature review of AS outcomes was conducted on July 22, 2021, according to PRISMA guidelines. The primary endpoint was the rate of conversion to secondary treatment. Secondary endpoints were progression-free survival, objective response rate (ORR), disease control rate (DCR), and adverse events. The rates of conversion to secondary treatment, ORRs, and DCRs were compared between the two groups using the Fisher's exact test.ResultsEighteen patients who received tranilast as the initial treatment for EADF were included. Two patients (11.1%) underwent surgical resection due to tumor growth and continuous pain. Compared to the secondary treatment conversion rate from the pure AS approach (40.1%), tranilast was shown to significantly reduce the rate (p = 0.01). The ORR and DCR did not different between the two groups.ConclusionsAs initial treatment for EADF, tranilast is preferred over AS.

    DOI： 10.1272/jnms.JNMS.2023_90-113

    PubMed

    researchmap

  • Prevalence and risk factors of preoperative venous thromboembolism in patients with malignant musculoskeletal tumors: an analysis based on D-dimer screening and imaging. 国際誌

    Kenta Hayashida, Yusuke Kawabata, Keiju Saito, Shintaro Fujita, Hyonmin Choe, Ikuma Kato, Masanobu Takeyama, Yutaka Inaba

    Thrombosis journal   20 ( 1 )   22 - 22   2022年4月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Venous thromboembolism (VTE) is a major complication in patients with malignant tumors and orthopedic disorders. Although it is known that patients undergoing surgery for malignant musculoskeletal tumor are at an increased risk of thromboembolic events, only few studies have investigated this risk in detail. Therefore, the aim of this study was to determine the prevalence and risk factors for preoperative VTE in malignant musculoskeletal tumors patients. METHODS: We retrospectively reviewed the medical records of 270 patients who underwent surgical procedures, including biopsy for malignant musculoskeletal tumor, have undergone measurements of preoperative D-dimer levels, and were subsequently screened for VTE by lower extremity venous ultrasonography and/or contrast-enhanced computed tomography scans. Statistical analyses were performed to examine the prevalence and risk factors for VTE. Receiver operating characteristic (ROC) analysis was performed to verify the D-dimer cutoff value for the diagnosis of VTE. RESULTS: Overall, 199 patients (103 with primary soft tissue sarcomas, 38 with primary bone sarcomas, 46 with metastatic tumors, and 12 with hematologic malignancies) were included. D-dimer levels were high in 79 patients; VTE was detected in 19 patients (9.5%). Multivariate analysis indicated that age ≥ 60 years (P = 0.021) and tumor location in the lower limbs (P = 0.048) were independent risk factors for VTE. ROC analysis showed that the D-dimer cutoff value for the diagnosis of VTE was 1.53 µg/mL; the sensitivity and specificity were 89.5% and 79.4%, respectively. CONCLUSIONS: Our study indicated that age and tumor location in the lower limbs were independent risk factors for preoperative VTE in malignant musculoskeletal tumors patients. D-dimer levels were not associated with VTE in the multivariate analysis, likely because they are affected by a wide variety of conditions, such as malignancy and aging. D-dimer is useful for exclusion diagnosis because of its high sensitivity, but patients with high age and tumor location in the lower limbs are a high-risk group and should be considered for imaging evaluation such as ultrasonography regardless of D-dimer levels. TRIAL REGISTRATION: Our study was approved by the institutional review board. The registration number is B200600056 . The registration date was July 13, 2020.

    DOI： 10.1186/s12959-022-00382-2

    PubMed

    researchmap

  • Characteristics of Patients with Giant Cell Tumor of Bone and High Serum Tartrate-Resistant Acid Phosphatase 5b Levels: Comparison of Tumor Volume and Clinical Factors.

    Kenta Hayashida, Yusuke Kawabata, Tomotaka Yoshida, Keiju Saito, Shintaro Fujita, Hyonmin Choe, Ikuma Kato, Masanobu Takeyama, Yutaka Inaba

    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi   89 ( 6 )   572 - 579   2022年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Serum tartrate-resistant acid phosphatase 5b is well known to be increased in giant cell tumors of bone. However, there are only a few studies that analyzed the association with tartrate-resistant acid phosphatase 5b expression in those patients. Therefore, we analyzed the characteristics of patients with giant cell tumors of bone and high tartrate-resistant acid phosphatase 5b expression. METHODS: This retrospective study included 26 patients with giant cell tumors of bone. The correlation between tartrate-resistant acid phosphatase 5b before initial treatment and tumor volume was evaluated. Patients were divided into two groups according to tartrate-resistant acid phosphatase 5b level. Statistical analysis was performed between the two groups. RESULTS: Tartrate-resistant acid phosphatase 5b was elevated in 17/26 patients, and the mean value was 852 mU/dL. There was no correlation with tumor volume (r = 0.034, P = 0.86). The mean age of 34.5 years in the HT group was significantly younger than the mean age of 47.4 years in the LT group (P = 0.040). Pathologically, 19/26 cases showed at least one focal area with features of typical giant cell tumor of bone. Although 11/18 patients in the LT group exhibited relatively noticeable secondary changes, all patients in the HT group exhibited typical features (P = 0.0074). CONCLUSIONS: Tartrate-resistant acid phosphatase 5b levels were not elevated in some giant cell tumors of bone. This study suggested that tartrate-resistant acid phosphatase 5b may be elevated in younger patients and in cases with fewer pathological secondary changes, regardless of tumor volume.

    DOI： 10.1272/jnms.JNMS.2022_89-611

    PubMed

    researchmap

  • オメガプラスTiツインフックを用いた大腿骨近位部骨折治療における、術後成績不良群の単純X線学的検討

    大庭 真俊, 竹内 剛, 沼崎 伸, 藤巻 洋, 草山 喜洋, 藤田 真太郎, 金 由梨, 森田 彰, 中澤 明尋

    骨折   40 ( Suppl. )   S234 - S234   2018年7月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本骨折治療学会  

    researchmap

  • 粘液型脂肪肉腫の悪性度判定を可能にするバイオマーカーの探索 査読

    根津 悠, 山本 雄介, 松尾 光祐, 竹元 暁, 鈴木 智士, 藤田 真太郎, 齋藤 知行, 落谷 孝広

    日本整形外科学会雑誌   90 ( 8 )   S1623 - S1623   2016年8月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本整形外科学会  

    researchmap

▼全件表示

MISC

▼全件表示